A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy.

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the skin may be just as effective as traditional means of administration with ...

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

A mid-stage study reveals that transdermal estradiol patches may match traditional androgen deprivation therapy in treating prostate cancer with fewer side effects. This approach boosts bone density ...

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

In recognition, the NFLPA will donate $100,000 to Slayton’s Left-Hand Right-Hand (LHRH) Foundation. “Winning this award means more than words can describe,” Slayton said. “The main goal ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...